Research

Hormonal

Pioglitazone (PPAR-gamma agonist) improves histological features of NASH but is limited by problematic weight gain and is not widely adopted.

Pioglitazone can improve liver histology in NASH patients (34% vs 19% placebo), but it causes weight gain and is not widely used. It is considered only when lifestyle changes fail and other options are not suitable.

GoodQualifiesHIGH confidence
The same trial also studied pioglitazone... and found some histological improvement in patients with NASH (34% vs 19% placebo, p=0.04) but this did not meet prespecified cut-offs for efficacy... problematic weight gain with pioglitazone, neither treatment has been widely adopted in clinical practice.
James Maurice et al. · Clinical Medicine · 2018

Why this rating

Based on a cited RCT (Sanyal et al.) with statistically significant histological improvement (p=0.04).

Source

Non-alcoholic fatty liver disease

James Maurice et al. · Clinical Medicine · 2018

DOI 10.7861/clinmedicine.18-3-245

narrative_reviewCited 347×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →